This inventor holds 2 USPTO granted patents. Top assignees: Duke University, The State University of New York. Active years: 1998-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998-2001
Title: Dmitry Y Goldgaber: Innovator in Amyloid Research
Introduction
Dmitry Y Goldgaber is a notable inventor based in Setauket, NY (US). He has made significant contributions to the field of biomedical research, particularly in the study of amyloid peptides. With a total of 2 patents, Goldgaber's work focuses on methods that have the potential to impact the understanding and treatment of amyloid-related diseases.
Latest Patents
Goldgaber's latest patents include a method of binding material to the β-amyloid peptide. This invention reveals that antibodies can bind to the β-amyloid peptide, which in turn binds to the hinge region of the immunoglobulin heavy chain. This interaction preserves the immunoglobulin's ability to bind to antigens. Additionally, he has developed methods for detecting soluble amyloid β-protein (βAP). This invention aims to prevent the aggregation of βAP, which is associated with amyloid deposition in the brain. His research identifies compounds like transthyretin that can form complexes with βAP, thereby preventing amyloid formation. Furthermore, Goldgaber's work highlights the serine 6 mutation in the TTR gene as a predictive marker for individuals at risk of developing βAP-associated amyloidosis.
Career Highlights
Throughout his career, Goldgaber has worked with prestigious institutions such as Duke University and The State University of New York. His research has contributed to a deeper understanding of amyloid-related conditions, paving the way for potential therapeutic approaches.
Collaborations
Goldgaber has collaborated with notable colleagues, including Warren J Strittmatter and Moises Eisenberg-Grunberg. These partnerships have enhanced the scope and impact of his research in the field of amyloid studies.
Conclusion
Dmitry Y Goldgaber's innovative work in amyloid research has led to significant advancements in understanding and potentially treating amyloid-related diseases. His contributions continue to influence the biomedical field and offer hope for future therapeutic developments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile